Nautilus Biotechnolgy Inc. (NAUT)
$2.25
$-0.04
(-1.53%)
As on 12-Jun-2026 13:41EDT
Market cap
$304 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
127,078,855
6 Years Aggregate
CFO
$-398.71 Mln
EBITDA
$434.89 Mln
Net Profit
$433.24 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nautilus Biotechnolgy (NAUT)
| 15.4 | -25.5 | -7.0 | 210.3 | -12.1 | -26.4 | -- |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Nautilus Biotechnolgy (NAUT)
| 16.1 | -43.5 | 66.1 | -65.3 | -52.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nautilus Biotechnolgy (NAUT)
|
2.3 | 303.7 | 0.0 | -57.1 | -- | -36.4 | -- | 2.4 |
| 283.0 | 40,461.0 | 4,286.9 | 577.2 | 9.8 | 88.2 | 76.3 | 37.6 | |
| 53.1 | 13,246.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 17.5 | 6.8 | |
| 131.2 | 16,655.9 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 179.4 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 | |
| 480.3 | 11,227.7 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 20.9 | |
| 468.8 | 12,973.2 | 2,678.3 | 460.4 | 21.1 | 103.2 | 28.6 | 21.9 | |
| 614.6 | 66,620.0 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 540.6 | 23,340.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.3 | 4.0 | |
| 444.1 | 113,407.9 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout Nautilus Biotechnolgy (NAUT)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform,... which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington. Read more
-
Co-Founder, CEO, President, Secretary & Director
Mr. Sujal M. Patel
-
Co-Founder, CEO, President, Secretary & Director
Mr. Sujal M. Patel
-
Headquarters
Seattle, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Nautilus Biotechnolgy (NAUT)
What is the current share price of Nautilus Biotechnolgy Inc (NAUT) Today?
The share price of Nautilus Biotechnolgy Inc (NAUT) is $2.25 (NASDAQ) as of 12-Jun-2026 13:41 EDT. Nautilus Biotechnolgy Inc (NAUT) has given a return of -12.07% in the last 3 years.
What is the current PB & PE ratio of Nautilus Biotechnolgy Inc (NAUT)?
Since, TTM earnings of Nautilus Biotechnolgy Inc (NAUT) is negative, P/E ratio is not available.
The P/B ratio of Nautilus Biotechnolgy Inc (NAUT) is 2.36 times as on 05-Jun-2026, a 42 discount to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.16
|
1.57
|
|
2024
|
-2.97
|
1.01
|
|
2023
|
-5.87
|
1.41
|
|
2022
|
-3.88
|
0.71
|
|
2021
|
-8.65
|
1.20
|
What is the 52 Week High and Low of Nautilus Biotechnolgy Inc (NAUT)?
The 52-week high and low of Nautilus Biotechnolgy Inc (NAUT) are Rs 4.31 and Rs 0.63 as of 13-Jun-2026.
What is the market cap of Nautilus Biotechnolgy Inc (NAUT)?
Nautilus Biotechnolgy Inc (NAUT) has a market capitalisation of $ 304 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Nautilus Biotechnolgy Inc (NAUT)?
Before investing in Nautilus Biotechnolgy Inc (NAUT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.